Kuros Biosciences AG
CSBTF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 45.2% | 37.3% | 53.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 88.7% | 77% | 89.1% | 84.2% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | -$0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | $0 | -$0 | $0 |
| Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Income | $0 | -$0 | -$0 | -$0 |
| % Margin | 5.5% | -10.1% | -1.8% | -41.9% |
| Other Income/Exp. Net | -$0 | -$0 | $0 | $0 |
| Pre-Tax Income | $0 | -$0 | $0 | -$0 |
| Tax Expense | $0 | -$0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.2% | -8% | -0.7% | -41.9% |
| EPS | -0.051 | -0.094 | -0.006 | -0.24 |
| % Growth | 46.3% | -1,552.6% | 97.6% | – |
| EPS Diluted | -0.051 | -0.094 | -0.006 | -0.24 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | -$0 | $0 | $0 |
| Interest Expense | $0 | -$0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $0 | -$0 | $0 | -$0 |
| % Margin | 7.1% | -2.2% | 1.2% | -14.9% |